Press Releases

Filter by:
October 20, 2023

IRRAS’s application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023
October 19, 2023

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB
October 19, 2023

IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting
October 16, 2023

IRRAS publishes prospectus
October 15, 2023

IRRAS has extended maturity date for its SEK 20 million short-term loan
October 13, 2023

Bulletin from the Extraordinary General Meeting in IRRAS AB (publ) on 13 October 2023
September 18, 2023

Statement by the Board of Directors of IRRAS AB
September 18, 2023

Notice to an extraordinary general meeting of IRRAS AB
September 15, 2023

IRRAS Secures Extended Short-Term Loan Agreement
August 24, 2023

Supplemental statement from the Independent Bid Committee of IRRAS regarding the public offer from IR Holding Bidco
August 24, 2023

IRRAS Publishes Update on Financial Situation
August 4, 2023

IRRAS publishes Interim Report for the period April to June 2023
August 4, 2023

IRRAS announces reassessment of financial outlook
August 4, 2023

IRRAS Secures Extended Short-Term Loan Agreement
August 2, 2023

Q2 Report 2023 – invitation to conference call and audiocast
July 23, 2023

Statement from the Independent Bid Committee of IRRAS regarding the public offer from IR Holding Bidco
June 30, 2023

Bulletin from the Annual General Meeting in IRRAS AB (publ) on 30 June 2023
June 30, 2023

Comment from the Independent Bid Committee of IRRAS regarding the public offer from IR Holding Bidco
June 29, 2023

IRRAS Shifts Commercial Strategy to Focus Resources on United States Market Opportunity and Publishes Financial Update
June 1, 2023

NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF IRRAS AB (PUBL)
May 17, 2023

IRRAS AB publishes Interim Report for the period January to March 2023
May 15, 2023

Q1 Report 2023 – invitation to conference call and audiocast
April 27, 2023

IRRAS publishes Annual Report for 2022
April 20, 2023

IRRAS Secures Short-term Financing Agreement of MSEK 40
February 16, 2023

IRRAS AB publishes Year End Report for the period January to December 2022
February 13, 2023

IRRAflow System Confirmed to More Effectively Remove Collected Blood and Reduce Catheter Infection Rates than Passive Drainage in Head-to-Head Analysis
February 9, 2023

Q4 Report 2022 – invitation to conference call and audiocast
February 1, 2023

IRRAS Announces Changed Publication Date for the Q4 2022 Interim Report
December 12, 2022

IRRAS Receives US FDA 510(k) Clearance for its Next Generation IRRAflow Control Unit
December 6, 2022

Nomination Committee for the IRRAS 2023 Annual General Meeting
November 14, 2022

IRRAS Announces Commercial Partnership with Medtronic in the United States for its IRRAflow[®] System
November 10, 2022

IRRAS AB publishes Interim Report for the period January to September 2022
November 3, 2022

Q3 Report 2022 – invitation to conference call and audiocast
October 13, 2022

IRRAS Announces Participation and Data Presentation at the 22nd European Congress of Neurosurgery
October 11, 2022

IRRAS Announces New Educational Webinar Series in Collaboration with the Jacobs Institute and the University of Buffalo Department of Neurosurgery
October 5, 2022

IRRAS Announces Participation and Educational Symposium at Key Upcoming Neurosurgery Conferences
September 30, 2022

Change in the total number of shares and votes in IRRAS AB
August 31, 2022

Change in the total number of shares and votes in IRRAS AB
August 24, 2022

IRRAS raises SEK 215 million in a rights issue
August 23, 2022

IRRAS Announces First Patient Treatments at Mount Sinai Health System in New York as Part of the DIVE Study
August 10, 2022

IRRAS Expands Short-term Financing Agreement
August 5, 2022

IRRAS publishes prospectus relating to the rights issue of approximately SEK 215 million
August 3, 2022

Bulletin from the Extraordinary General Meeting in IRRAS AB (publ) on 3 August 2022
July 22, 2022

IRRAS AB publishes Interim Report for the period January to June 2022
July 15, 2022

Q2 Report 2022 – invitation to conference call and audiocast
July 4, 2022

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB (PUBL)
July 4, 2022

IRRAS intends to carry out a rights issue of up to SEK 215 million
July 4, 2022

IRRAS Presents Business Update and New Financial Targets
May 24, 2022

Bulletin from the Annual General Meeting in IRRAS AB (publ) on 24 May 2022
May 19, 2022

IRRAS Secures Short-term Financing Agreement of MSEK 30
April 29, 2022

IRRAS publishes annual report for 2021
April 27, 2022

IRRAS AB publishes Interim Report for the period January to March 2022
April 25, 2022

NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF IRRAS AB (PUBL)
April 25, 2022

IRRAS Announces Changed Publication Date for the Q1 2022 Interim Report
March 11, 2022

IRRAS Announces Regulatory Approval of IRRAflow[ ]in Australia
March 3, 2022

IRRAS Announces First Global Patient Treatment with Next-Generation IRRAflow[®][ ]System
February 22, 2022

IRRAS Launches Next-Generation of the IRRAflow System in the United States
February 16, 2022

IRRAS AB publishes Year End Report for the period January to December 2021
February 10, 2022

Q4 Report 2021 – invitation to conference call and audiocast
February 10, 2022

Presentation of Largest Dataset to Date Documenting Use of IRRAflow System Confirms Improved Outcomes Compared to Traditional Drainage Solutions
January 28, 2022

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow’s Efficacy to Traditional Passive Drainage
January 12, 2022

IRRAS Expands Intellectual Property Portfolio with Issuance of Additional Patent for IRRAflow System
December 23, 2021

IRRAS Partners with Lovell Government Services to Expand Distribution Capabilities to United States Military Service Members and Veterans
December 3, 2021

Nomination Committee for the IRRAS 2022 Annual General Meeting
November 9, 2021

IRRAS AB publishes Interim Report for the period, January to September 2021
November 4, 2021

Q3 Report 2021 – invitation to conference call and audiocast
October 28, 2021

IRRAS Accounces Announces First Patient Enrolled in ARCH Study, a Comparative Clinical Trial Designed to Confirm IRRAflow’s Ability to Improve Clearance of Clot after IVH
October 22, 2021

IRRAS Announces Collaboration with Aarhus University to Develop Software that Calculates Brain Compliance using its IRRAflow System
October 15, 2021

IRRAS Accounces Participation and Data Presentations at Two Upcoming, In-Person Neurosurgery Conferences
October 12, 2021

Aarhus University Hospital, a Globally Leading Medical Institution, Begins Use of IRRAS’ IRRAflow System and Initiates Clinical Study to Validate its Efficacy
October 7, 2021

IRRAS Announces CE Mark Approval for its Enhanced IRRAflow Dual-Lumen Catheter
September 29, 2021

IRRAS’ IRRAflow[®] System Demonstrates Ability to Treat Pyogenic Ventriculitis through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open
August 26, 2021

IRRAS AB publishes Interim Report for the period, January to June 2021
August 19, 2021

Q2 Report 2021 – invitation to conference call and audiocast
July 29, 2021

IRRAS receives loan financing under European Guarantee Fund
July 21, 2021

IRRAS receives extension of its MDSAP certification and scope expansion of MDSAP & ISO 13485:2016 certifications
July 15, 2021

Bulletin from Extraordinary General Meeting in IRRAS on July 15, 2021
July 1, 2021

Will Martin Assumes Role as President and Chief Executive Officer of IRRAS
June 30, 2021

Change in the total number of shares and votes in IRRAS AB
June 23, 2021

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB (PUBL)
June 18, 2021

IRRAS announces changes to management team
June 10, 2021

IRRAS has carried out a directed share issue of 13,200,00 shares at a subscription price of SEK 5 per share
June 10, 2021

IRRAS intends to carry out a directed issue of shares
June 8, 2021

IRRAS Receives Quality System Certification under MDSAP and Updated European Union Medical Device Regulation 2017 / 745
May 28, 2021

IRRAS Announces publication of a Case report from Buffalo General Medical Center, highlights clinical superiority of IRRAflow treatment versus traditional drainage
May 25, 2021

IRRAS receives forgivness for loan from US Stimulus Package
May 11, 2021

IRRAS Announces Notified Body Transition from GMED to DEKRA, a Global Leader in Inspection and Certifications
May 4, 2021

IRRAS AB publishes Interim Report for the period January to March 2021
April 28, 2021

Bulletin from Annual General Meeting in IRRAS on April 28, 2021
April 21, 2021

IRRAS Promotes Will Martin to Chief Executive Officer
April 6, 2021

IRRAS Announces Collaboration with Aarhus University Hospital, Scandinavian Leader in Neurosurgery, to Advance Use of IRRAflow
March 30, 2021

Notice to attend the Annual General Meeting of IRRAS AB (publ)
March 30, 2021

IRRAS publishes annual report for 2020
March 23, 2021

IRRAS to Present at Redeye
March 9, 2021

IRRAS Announces the recruitment of Sten Gustafsson as Director of Investor Relations
February 16, 2021

IRRAS AB publishes Year End Report for the period January to December 2020
February 9, 2021

Q4 Report 2020 – invitation to conference call and audiocast
January 12, 2021

IRRAS Announces Collaboration with Karolinska University Hospital
December 17, 2020

IRRAS Announces Expansion of IRRAflow Launch to Southeastern Europe
December 10, 2020

IRRAS Announces Expansion of IRRAflow Launch to Latin America
November 26, 2020

IRRAS Announces Expansion of IRRAflow Launch to The Netherlands
November 17, 2020

IRRAS Awarded Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products
November 10, 2020

IRRAS AB publishes Interim Report for the period January to September 2020
November 4, 2020

Q3 Report 2020 – invitation to conference call and audiocast
October 22, 2020

IRRAS Announces Key IRRAflow Commercial Milestones in Germany
September 29, 2020

IRRAS Announces Release of Clinical Data that Validates Safety and Effectiveness of IRRAflow System in Treating Chronic Subdural Hematomas
September 22, 2020

IRRAS Enhances Global Sales Organization, Adds Key Talent to Drive Adoption of its IRRAflow and Hummingbird Product Lines
August 27, 2020

IRRAS AB publishes Interim Report for the period January to June 2020
August 25, 2020

IRRAS Granted Sixth Patent for Hummingbird ICP Monitoring Product Line from United States Patent and Trademark Office (USPTO)
August 20, 2020

Q2 Report 2020 – invitation to conference call and audiocast
August 18, 2020

Anders P. Wiklund, Chairman of the Board of Directors of IRRAS AB, has passed away
August 11, 2020

IRRAS Announces First Global Patient Treatment with Newly Developed Hummingbird Solo ICP Monitoring System
August 5, 2020

IRRAS to Present Virtually at Upcoming Investor Conferences
July 22, 2020

IRRAS Announces Extension of CE Mark for IRRAflow System until May 2024
June 30, 2020

Covid-19 delays short term revenue, while the commercial launch of IRRAflow and Hummingbird progresses
June 15, 2020

IRRAS Announces Promotion of Will Martin to President and Chief Commercial Officer
May 19, 2020

IRRAS has been approved for listing on Nasdaq Stockholm and publishes prospectus
May 14, 2020

IRRAS AB publishes Interim Report for the period January to March 2020
May 11, 2020

Q1 Report 2020 – invitation to conference call and audiocast
May 7, 2020

IRRAS to list on Nasdaq Stockholm
May 4, 2020

IRRAS receives approval for loan from US Stimulus Package
April 28, 2020

Bulletin from Annual General Meeting in IRRAS on April 28, 2020
April 14, 2020

IRRAS announces outcome of the fully guaranteed rights issue of 217 MSEK
March 26, 2020

Correction of press release: IRRAS publishes prospectus relating to the rights issue of approximately SEK 217 million
March 25, 2020

University of Helsinki, a Global Neurosurgery Leader and IRRAS will Collaborate to Advance Uses of IRRAflow
March 24, 2020

IRRAS publishes prospectus relating to the rights issue of approximately SEK 217 million
March 20, 2020

IRRAS publishes annual report for 2019
March 17, 2020

IRRAS’ Board of Directors resolves on a fully underwritten rights issue of approximately SEK 217 million
February 14, 2020

IRRAS AB publishes Interim Report for the period January to December 2019
January 30, 2020

Q4 Report 2019 – invitation to conference call and audiocast
January 7, 2020

IRRAS Provides US Launch Update, Product Portfolio Progress and Objectives for 2020
December 19, 2019

IRRAS Receives Renewed CE Mark for the IRRAflow Catheter
December 16, 2019

IRRAS Announces US Launch of Hummingbird Products for Neurocritical Care
December 9, 2019

IRRAflow[®] Wins CONNECT’s “2019 Most Innovative New Product” Award
November 21, 2019

IRRAS Announces FDA Clearance of New 510(K) Filing to Expand the Time of Use of IRRAflow®
November 14, 2019

IRRAS AB publishes Interim Report for the period January to September 2019
November 11, 2019

IRRAS Announces Addition of Dr. Coenraad Tamse as Vice President, International Sales
October 31, 2019

Q3 Report 2019 – invitation to conference call and audiocast
October 18, 2019

IRRAS Announces Participation at the 69th Congress of Neurological Surgeons’ Annual Meeting (CNS 2019)
October 15, 2019

IRRAS to Present at the 17th Neurocritical Care Society’s Annual Meeting
September 24, 2019

IRRAS Announces Participation at the 19th European Congress of Neurosurgery
September 13, 2019

IRRAS announces changes in management and key hires with leadership roles in Regulatory Affairs and Hummingbird Product Line
August 29, 2019

Q2 Report 2019 – invitation to conference call and audiocast
August 29, 2019

IRRAS publishes Interim Report for the period January to June 2019
August 1, 2019

IRRAS Announces Issuance of New Patent for Core IRRAflow® Technology
June 25, 2019

IRRAS wins regulatory approval of IRRAflow® in Israel and Costa Rica
June 18, 2019

IRRAS announces changes in management group
May 22, 2019

IRRAS has completed a directed share issue of approximately SEK 106 million
May 22, 2019

IRRAS intends to make a directed share issue
May 14, 2019

Bulletin from Annual General Meeting in IRRAS on May 14, 2019
May 7, 2019

IRRAS AB – Q1 Report 2019 – invitation to conference call and webcast
May 7, 2019

IRRAS AB (PUBL)INTERIM REPORT JANUARY–MARCH 2019
May 7, 2019

IRRAS strengthens position in neurocritical care by acquiring proprietary assets, including four US FDA-cleared products
May 3, 2019

IRRAS’s nomination committee proposes Ms. Catherine Gilmore-Lawless as new board member
April 24, 2019

IRRAS Provides Update on CE Mark Re-Certification of IRRAflow®
April 23, 2019

IRRAS publishes the 2018 Annual Report
April 23, 2019

IRRAS Establishes Collaborative Relationship with AMI-USC Through Acquisition of Complementary Medical Device Technology
April 15, 2019

NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF IRRAS AB (PUBL)
March 13, 2019

IRRAS evaluates a possible listing of the company’s share on Nasdaq Stockholm’s main market during 2019
March 11, 2019

IRRAS Strengthens Executive Team with Addition of Dr. Vinny Podichetty as Vice President of Clinical Affairs
March 6, 2019

IRRAS presents new financial targets
February 14, 2019

IRRAS AB (PUBL) YEAR-END REPORT JANUARY–DECEMBER 2018
February 13, 2019

IRRAS AB – Q4 Report 2018 – invitation to conference call and webcast
January 10, 2019

First Patient in the United States Successfully Treated with IRRAflow®
January 3, 2019

IRRAS Enters into Global Partnership with HealthLink to Support Distributors of IRRAS’ Medical Products
November 8, 2018

IRRAS AB (PUBL) INTERIM REPORT JANUARY–SEPTEMBER 2018
November 7, 2018

IRRAS AB – Q3 Report 2018 – invitation to conference call and webcast
October 19, 2018

IRRAS EXPANDS ITS MANAGEMENT GROUP
October 15, 2018

IRRAS EXPANDS ITS PRODUCT DEVELOPMENT AND MANUFACTURING TEAM IN THE U.S. WITH THE HIRING OF KEY TALENTED PROFESSIONALS
October 4, 2018

IRRAS Provides Update on the Recertification Process of the CE Mark for the IRRAflow® Catheter
October 3, 2018

IRRAS TO PARTICIPATE IN KEY UPCOMING NEUROSURGERY CONFERENCES
October 1, 2018

Eva Nilsagård elected new IRRAS board member
September 27, 2018

IRRAS STRENGTHENS US COMMERCIAL ORGANIZATION WITH HIRING OF MULTIPLE KEY TALENTS
September 13, 2018

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING IN IRRAS AB (PUBL)
August 27, 2018

IRRAS AB (Publ) INTERIM FINANCIAL REPORT JANUARY – JUNE 2018
August 24, 2018

IRRAS AB – Q2 Report 2018 – invitation to conference call and webcast
July 16, 2018

IRRAS Receives FDA Clearance for IRRAflow® in the US
June 1, 2018

Bulletin from Annual General Meeting in IRRAS AB on June 1, 2018
May 29, 2018

Solid sales in the quarter and updated CE approval partially in place
May 28, 2018

IRRAS AB – Q1 Report 2018 – invitation to conference call and webcast
May 11, 2018

IRRAS publishes the 2017 Annual Report
May 9, 2018

IRRAS appoints Dr. Christos Panotopoulos to new role as Special Advisor and a member of the IRRAS Clinical Advisory Board
May 9, 2018

IRRAS announces receipt of updated ISO 13485:2016 certificate and updated CE marks valid until 2021 for two of three IRRAflow™ products –
May 3, 2018

NOTICE TO ATTEND THE ANNUAL GENERAL MEETING OF IRRAS AB (PUBL)
March 12, 2018

IRRAS Provides Update on FDA 510(k) Application of IRRAflow™
March 5, 2018

IRRAS Appoints Will Martin as Chief Commercial Officer
February 28, 2018

IRRAS strengthens executive team with appointment of Kellie Fontes as Senior Director of Human Capital
February 21, 2018

IRRAS AB (PUBL) YEAR-END REPORT 2017
February 20, 2018

IRRAS AB – Year-end Report 2017 – invitation to conference call and webcast
January 18, 2018

IRRAS introduces IRRAflowTM v 2.5 with several upgrades including an updated battery configuration
December 22, 2017

ABG Sundal Collier has notified IRRAS that stabilisation measures regarding IRRAS´ shares have been effected and that the stabilisation period ends
December 13, 2017

IRRAS announces voluntary recall on its IRRAflow™ device due to an isolated incident of a battery manufacturing failure
November 30, 2017

ABG Sundal Collier AB has notified IRRAS AB (“IRRAS” or the ”Company”) that stabilisation measures regarding the Company’s shares have been effected.
November 23, 2017

Announcement of acquisitions of shares in IRRAS made by board members and senior management in the Company
November 23, 2017

Board members and senior management in IRRAS have notified their intention to acquire shares in the Company
November 22, 2017

Final price in IRRAS initial public offering set – trading on Nasdaq First North Premier commences today
November 13, 2017

IRRAS announces initial public offering and publishes prospectus for listing on Nasdaq First North Premier
September 13, 2017

IRRAS Strengthens Executive and Commercial Teams with Appointments of Karl-Matthias Moehlmann and Klemens Fölling
August 29, 2017

IRRAS Appoints Fredrik Alpsten as Chief Financial Officer and Deputy CEO
April 10, 2017

IRRAS Appoints Medical Technology Leader C. Lance Boling as Vice President, Product Development